Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance

AIDS Research and Human Retroviruses

Volumn 19, Issue 8, 2003, Pages 653-656

  Campo, Rafael E ^a   Rosa, Isabella ^a   Lichtenberger, Paola N ^a   Suarez, German ^a   Rivera, Fernando A ^a   Jayaweera, Dushyantha T ^a   Rodriguez, Allan E ^a   Wahlay, Natalie A ^a   Kolber, Michael A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; GENOTYPE; GROWTH INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROPREVALENCE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRAL GENETICS; VIROGENESIS;

ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0042825484     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203322280865     Document Type: Article

References (11)

1. Lucas GM, Chaisson RE, and Moore RD: Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-87.
2. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA 2000;282:2417-2426.
3. Devereux HL, Youle M, Johnson MA, and Loveday C: Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123-F127.
4. Izopet J, Massip P, Souyris C, et al.: Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 2000;14:2247-2255.
5. Verhofstede C, Van Wanzeele F, Van der Gucht B, De Cabooter N, and Plum J: Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reapperance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999;13:2541-2546.
6. Birk M, Svedhem V, and Sonnerborg A: Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 2001;15:1359-1368.
7. Deeks SG, Wrin T, Liegler T, et al.: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-480.
8. Garcia-Lerma JG and Heneine W: Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: Genotypic and phenotypic testing. J Clin Virol 2001;21:197-212.
9. Miller V, Sabin C, Hertogs K, et al.: Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000;14:2857-2867.
10. Descamps D, Flandre P, Calvez V, et al.: Mechanisms of virological failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000;283:205-211.
11. Havlir DV, Hellman NS, Petropoulos CJ, et al.: Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000;283:229-234.